Antifungal Drug Development: Challenges, Unmet Clinical Needs, and New Approaches
Open accessThe DOI matches its Crossref record; 77 of the 78 references it cites were found in a registry or an index.
Abstract
Invasive, life-threatening fungal infections are an important cause of morbidity and mortality, particularly for patients with compromised immune function. The number of therapeutic options for the treatment of invasive fungal infections is quite limited when compared with those available to treat bacterial infections. Indeed, only three classes of molecules are currently used in clinical practice and only one new class of antifungal drugs has been developed in the last 30 years. Here we summarize the unmet clinical needs of current antifungal therapy, discuss challenges inherent to antifungal drug discovery and development, and review recent developments aimed at addressing some of these challenges.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Organelles such as the vacuole make important contributions to tolerance and/or trailing growth.”
From Drug resistance and tolerance in fungi. (2020) · cites this paper as [94]
In the citing paper
“In Saccharomyces cerevisiae several genes involved in retrograde trafficking modulate tolerance and/or trailing growth, including VPS2127,51, VPS15 and VPS5194; Rim101 may influence tolerance via its ability to regulate the transcription of key components of the vacuolar trafficking pathway95.”
From Drug resistance and tolerance in fungi. (2020) · cites this paper as [94]
In the citing paper
“Despite extensive efforts, target-based cell-free screening of synthetic chemical libraries has failed to deliver any new classes of antifungals or antibacterials in clinical practice (Payne et al., 2007; Roemer and Krysan, 2014).”
From A Fungal-Selective Cytochrome bc1 Inhibitor Impairs Virulence and Prevents the Evolution of Drug Resistance (2016) · cites this paper as Roemer and Krysan, 2014
Citations
Cites
Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
Boucher, H. W., Talbot, G. H., Bradley, J. S., Edwards, J. E., Gilbert, D., Rice, L. B., Scheld, M., Spellberg, B., & Bartlett, J. (2009) · Clinical Infectious Diseases · doi:10.1086/595011 · Cited by 4,958
Functional profiling of the Saccharomyces cerevisiae genome
Giaever, G., Chu, A. M., Ni, L., Connelly, C., Riles, L., Véronneau, S., Dow, S., Lucau-Danila, A., Anderson, K., André, B., et al. (2002) · Nature · doi:10.1038/nature00935 · Cited by 4,316
Hidden Killers: Human Fungal Infections
Brown, G. D., Denning, D. W., Gow, N. A. R., Levitz, S. M., Netea, M. G., & White, T. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004404 · Cited by 4,284
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E., Oestmann, J.-W., Kern, W. V., Marr, K. A., Ribaud, P., Lortholary, O., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020191 · Cited by 3,304
Drugs for bad bugs: confronting the challenges of antibacterial discovery
Payne, D. J., Gwynn, M. N., Holmes, D. J., & Pompliano, D. L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2201 · Cited by 2,512
The Genetic Landscape of a Cell
Costanzo, M., Baryshnikova, A., Bellay, J., Kim, Y., Spear, E. D., Sevier, C. S., Ding, H., Koh, J. L. Y., Toufighi, K., Mostafavi, S., et al. (2010) · Science · doi:10.1126/science.1180823 · Cited by 2,162
Park, B. J., Wannemuehler, K. A., Marston, B. J., Govender, N., Pappas, P. G., & Chiller, T. M. (2009) · AIDS · doi:10.1097/qad.0b013e328322ffac · Cited by 2,014
Platforms for antibiotic discovery
Lewis, K. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3975 · Cited by 1,445
Pierce, C. G., Uppuluri, P., Tristan, A. R., Wormley, F. L., Mowat, E., Ramage, G., & Lopez-Ribot, J. L. (2008) · Nature Protocols · doi:10.1038/nprot.2008.141 · Cited by 1,041
Amphotericin B formulations: a comparative review of efficacy and toxicity
Hamill, R. J. (2013) · Drugs · doi:10.1007/s40265-013-0069-4 · Cited by 807
Cited by
The re-emergence of natural products for drug discovery in the genomics era
Harvey, A. L., Edrada-Ebel, R., & Quinn, R. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4510 · Cited by 2,572
Antifungal Drug Resistance: Molecular Mechanisms in Candida albicans and Beyond
Lee, Y., Puumala, E., Robbins, N., & Cowen, L. E. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00199 · Cited by 801
Drug resistance and tolerance in fungi.
Berman, J., & Krysan, D. J. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0322-2 · Cited by 642
Self-citationPathogenesis and virulence of Candida albicans
Lopes, J. P., & Lionakis, M. S. (2022) · Virulence · doi:10.1080/21505594.2021.2019950 · Cited by 477
Anti-Fungal Efficacy and Mechanisms of Flavonoids
Al Aboody, M. S., & Mickymaray, S. (2020) · Antibiotics · doi:10.3390/antibiotics9020045 · Cited by 472
Campoy, S., & Adrio, J. L. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.11.019 · Cited by 511
Molecular Evolution of Antifungal Drug Resistance
Robbins, N., Caplan, T., & Cowen, L. E. (2017) · Annual Review of Microbiology · doi:10.1146/annurev-micro-030117-020345 · Cited by 441
Molecular mechanisms governing antifungal drug resistance
Lee, Y., Robbins, N., & Cowen, L. E. (2023) · npj Antimicrobials and Resistance · doi:10.1038/s44259-023-00007-2 · Cited by 304
“While azoles are well tolerated, a signi fi cant drawback is their potential to disrupt the metabolism of other drugs, as they also inhibit mammalian cytochrome P450 5 .”
InfluentialShafiei, M., Peyton, L., Hashemzadeh, M., & Foroumadi, A. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104240 · Cited by 295
F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase
Oliver, J. D., Sibley, G. E. M., Beckmann, N., Dobb, K. S., Slater, M. J., McEntee, L., du Pré, S., Livermore, J., Bromley, M. J., Wiederhold, N. P., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1608304113 · Cited by 289
Antifungal Peptides as Therapeutic Agents
Fernández de Ullivarri, M., Arbulu, S., Garcia-Gutierrez, E., & Cotter, P. D. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00105 · Cited by 264
Antifungal Drugs: The Current Armamentarium and Development of New Agents
Robbins, N., Wright, G. D., & Cowen, L. E. (2016) · Microbiology Spectrum · doi:10.1128/microbiolspec.funk-0002-2016 · Cited by 271
Single-cell analysis of cardiogenesis reveals basis for organ-level developmental defects
de Soysa, T. Y., Ranade, S. S., Okawa, S., Ravichandran, S., Huang, Y., Salunga, H. T., Schricker, A., del Sol, A., Gifford, C. A., & Srivastava, D. (2019) · Nature · doi:10.1038/s41586-019-1414-x · Cited by 266
Combinatorial strategies for combating invasive fungal infections
Spitzer, M., Robbins, N., & Wright, G. D. (2017) · Virulence · doi:10.1080/21505594.2016.1196300 · Cited by 218
Antifungals discovery: an insight into new strategies to combat antifungal resistance
Fuentefria, A. M., Pippi, B., Dalla Lana, D. F., Donato, K. K., & de Andrade, S. F. (2018) · Letters in Applied Microbiology · doi:10.1111/lam.12820 · Cited by 206
Antifungals: Mechanism of Action and Drug Resistance
Prasad, R., Shah, A. H., & Rawal, M. K. (2016) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-25304-6_14 · Cited by 183
New facets of antifungal therapy
Chang, Y.-L., Yu, S.-J., Heitman, J., Wellington, M., & Chen, Y.-L. (2017) · Virulence · doi:10.1080/21505594.2016.1257457 · Cited by 161
Data Resources for the Computer-Guided Discovery of Bioactive Natural Products
Chen, Y., de Bruyn Kops, C., & Kirchmair, J. (2017) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.7b00341 · Cited by 161
Lino, C. I., Gonçalves de Souza, I., Borelli, B. M., Silvério Matos, T. T., Santos Teixeira, I. N., Ramos, J. P., Maria de Souza Fagundes, E., de Oliveira Fernandes, P., Maltarollo, V. G., Johann, S., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.03.083 · Cited by 162
Martinez-Rossi, N. M., Peres, N. T. A., Bitencourt, T. A., Martins, M. P., & Rossi, A. (2021) · Journal of Fungi · doi:10.3390/jof7080629 · Cited by 162
Shih, P.-Y., Liao, Y.-T., Tseng, Y.-K., Deng, F.-S., & Lin, C.-H. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00602 · Cited by 156
“Two cell wall-disturbing (calcofluor white and caspofungin) agents and one cell membrane-disturbing (SDS) agent were therefore chosen for use in sensitivity assays (Roncero and Duran, 1985; Ram et al., 1994).”
MethodFunctionalized niosomes as a smart delivery device in cancer and fungal infection
Aparajay, P., & Dev, A. (2021) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2021.106052 · Cited by 153
Combatting the evolution of antifungal resistance in Cryptococcus neoformans
Bermas, A., & Geddes‐McAlister, J. (2020) · Molecular Microbiology · doi:10.1111/mmi.14565 · Cited by 155
Expandable and reversible copy number amplification drives rapid adaptation to antifungal drugs
Todd, R. T., & Selmecki, A. (2020) · eLife · doi:10.7554/elife.58349 · Cited by 138
Catalytic approaches to assemble cyclobutane motifs in natural product synthesis
Wang, M., & Lu, P. (2017) · Organic Chemistry Frontiers · doi:10.1039/c7qo00668c · Cited by 136
Tackling Fungal Resistance by Biofilm Inhibitors
Wu, S., Wang, Y., Liu, N., Dong, G., & Sheng, C. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01203 · Cited by 135
Liposomes: Biomedical Applications
Kim, E., & Jeong, H. (2021) · Chonnam Medical Journal · doi:10.4068/cmj.2021.57.1.27 · Cited by 143
The Antifungal Activity of Naphthoquinones: An Integrative Review
Futuro, D. O., Ferreira, P. G., Nicoletti, C. D., Borba-Santos, L. P., da Silva, F. D. C., Rozental, S., & Ferreira, V. F. (2018) · Anais da Academia Brasileira de Ciências · doi:10.1590/0001-3765201820170815 · Cited by 135
Emerging New Targets for the Treatment of Resistant Fungal Infections
Liu, N., Tu, J., Dong, G., Wang, Y., & Sheng, C. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01413 · Cited by 139
A Bacterial Symbiont Protects Honey Bees from Fungal Disease
Miller, D. L., Smith, E. A., & Newton, I. L. G. (2021) · mBio · doi:10.1128/mbio.00503-21 · Cited by 137
MOFs and MOF-Derived Materials for Antibacterial Application
Zhang, X., Peng, F., & Wang, D. (2022) · Journal of Functional Biomaterials · doi:10.3390/jfb13040215 · Cited by 129
Thammahong, A., Puttikamonkul, S., Perfect, J. R., Brennan, R. G., & Cramer, R. A. (2017) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00053-16 · Cited by 125
Fungal diseases: could nanostructured drug delivery systems be a novel paradigm for therapy?
Voltan, A. R., Quindós, G., Medina‐Alarcón, K. P., Fusco‐Almeida, A. M., Mendes‐Giannini, M. J. S., & Chorilli, M. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s93105 · Cited by 126
Pierce, C. G., Chaturvedi, A. K., Lazzell, A. L., Powell, A. T., Saville, S. P., McHardy, S. F., & Lopez-Ribot, J. L. (2015) · npj Biofilms and Microbiomes · doi:10.1038/npjbiofilms.2015.12 · Cited by 124
The Future of Antifungal Drug Therapy: Novel Compounds and Targets
Mota Fernandes, C., Dasilva, D., Haranahalli, K., McCarthy, J. B., Mallamo, J., Ojima, I., & Del Poeta, M. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01719-20 · Cited by 124
Amphotericin B containing microneedle ocular patch for effective treatment of fungal keratitis
Roy, G., Galigama, R. D., Thorat, V. S., Mallela, L. S., Roy, S., Garg, P., & Venuganti, V. V. K. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.118808 · Cited by 123
A holistic review on Cryptococcus neoformans
Rathore, S. S., Sathiyamoorthy, J., Cheepurupalli, L., & Ramakrishnan, J. (2022) · Microbial Pathogenesis · doi:10.1016/j.micpath.2022.105521 · Cited by 136
Major challenges and perspectives in the diagnostics and treatment of dermatophyte infections
Gnat, S., Łagowski, D., & Nowakiewicz, A. (2020) · Journal of Applied Microbiology · doi:10.1111/jam.14611 · Cited by 135
Structural basis for inhibition and regulation of a chitin synthase from Candida albicans
Ren, Z., Chhetri, A., Guan, Z., Suo, Y., Yokoyama, K., & Lee, S. (2022) · Nature Structural & Molecular Biology · doi:10.1038/s41594-022-00791-x · Cited by 123
Brown, A. J. P., Cowen, L. E., Pietro, A. D., & Quinn, J. (2017) · Microbiology Spectrum · doi:10.1128/microbiolspec.funk-0048-2016 · Cited by 125
Akbar, S., Zou, Q., Raza, A., & Alarfaj, F. (2024) · Artif. Intell. Medicine · doi:10.1016/j.artmed.2024.102860 · Cited by 108
Antifungal Properties of Zinc Oxide Nanoparticles on Candida albicans
Djearamane, S., Xiu, L.-J., Wong, L. S., Rajamani, R., Bharathi, D., Kayarohanam, S., Cruz, A. E. D., Tey, L., Janakiraman, A. K., Aminuzzaman, M., et al. (2022) · Coatings · doi:10.3390/coatings12121864 · Cited by 106
Novel 1, 2, 4‐Triazoles as Antifungal Agents
Kazeminejad, Z., Marzi, M., Shiroudi, A., Kouhpayeh, S. A., Farjam, M., & Zarenezhad, E. (2022) · BioMed Research International · doi:10.1155/2022/4584846 · Cited by 102
System-level impact of mitochondria on fungal virulence: to metabolism and beyond
Calderone, R., Li, D., & Traven, A. (2015) · FEMS Yeast Research · doi:10.1093/femsyr/fov027 · Cited by 101
Copper at the Fungal Pathogen-Host Axis
García‐Santamarina, S., & Thiele, D. J. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.r115.649129 · Cited by 106
The pore-forming action of polyenes: From model membranes to living organisms
Kristanc, L., Božič, B., Jokhadar, Š. Z., Dolenc, M. S., & Gomišček, G. (2018) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2018.11.006 · Cited by 110
Antibacterial carbonic anhydrase inhibitors: an update on the recent literature
Supuran, C. T., & Capasso, C. (2020) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2020.1811853 · Cited by 97
Sphingolipids as Targets for Treatment of Fungal Infections
Rollin‐Pinheiro, R., Singh, A., Barreto‐Bergter, E., & Poeta, M. D. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0053 · Cited by 108
Turecka, K., Chylewska, A., Kawiak, A., & Waleron, K. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01594 · Cited by 101
Parente-Rocha, J. A., Bailão, A. M., Amaral, A. C., Taborda, C. P., Paccez, J. D., Borges, C. L., & Pereira, M. (2017) · Mediators of Inflammation · doi:10.1155/2017/9870679 · Cited by 102
Mann, P. A., McLellan, C. A., Koseoglu, S., Si, Q., Kuzmin, E., Flattery, A. M., Harris, G. H., Sher, X., Murgolo, N., Wang, H., et al. (2014) · ACS Infectious Diseases · doi:10.1021/id5000212 · Cited by 90
Self-citationMitochondrial dysfunctions trigger the calcium signaling-dependent fungal multidrug resistance
Li, Y., Zhang, Y., Zhang, C., Wang, H., Wei, X., Chen, P., & Lü, L. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1911560116 · Cited by 88
Development and research progress of anti-drug resistant fungal drugs
Cui, X., Wang, L., Lü, Y., & Yue, C. (2022) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2022.08.004 · Cited by 85
Methods of Controlling Invasive Fungal Infections Using CD8+ T Cells
Kumaresan, P. R., da Silva, T. A., & Kontoyiannis, D. P. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01939 · Cited by 85
Epigenetic mechanisms of drug resistance in fungi
Chang, Z., Yadav, V., Lee, S. C., & Heitman, J. (2019) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2019.103253 · Cited by 85
Rapidly dissolving microneedle patch of amphotericin B for intracorneal fungal infections
Albadr, A. A., Tekko, I. A., Vora, L. K., Ali, A., Laverty, G., Donnelly, R. F., & Singh, T. R. R. (2021) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-01032-2 · Cited by 87
Koselny, K., Green, J., DiDone, L., Halterman, J. P., Fothergill, A. W., Wiederhold, N. P., Patterson, T. F., Cushion, M. T., Rappelye, C., Wellington, M., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01061-16 · Cited by 83
Self-citationFernández-García, R., de Pablo, E., Ballesteros, M. P., & Serrano, D. R. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.04.013 · Cited by 77
Biernasiuk, A., Baj, T., & Malm, A. (2022) · Molecules · doi:10.3390/molecules28010215 · Cited by 83
The anti- Aspergillus drug pipeline: Is the glass half full or empty?: Table 1.
Osherov, N., & Kontoyiannis, D. P. (2016) · Medical Mycology · doi:10.1093/mmy/myw060 · Cited by 81
Wurster, S., Watowich, S. S., & Kontoyiannis, D. P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1018202 · Cited by 79
Veloso, D. F. M. C., Benedetti, N. I. G. M., de Ávila, R. I., Bastos, T. S. A., Silva, T. C., Silva, M. R. R., Batista, A. C., Valadares, M. C., & Lima, E. M. (2018) · Drug Delivery · doi:10.1080/10717544.2018.1492046 · Cited by 74
Biernasiuk, A., Berecka-Rycerz, A., Gumieniczek, A., Malm, M., Łączkowski, K. Z., Szymańska, J., & Malm, A. (2021) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-021-11477-7 · Cited by 72
Antifungal Efficacy of Marine Macroalgae against Fungal Isolates from Bronchial Asthmatic Cases
Mickymaray, S., & Alturaiki, W. (2018) · Molecules · doi:10.3390/molecules23113032 · Cited by 72
Kim, J. H., Cheng, L. W., Chan, K. L., Tam, C. C., Mahoney, N., Friedman, M., Shilman, M. M., & Land, K. M. (2020) · Antibiotics · doi:10.3390/antibiotics9110812 · Cited by 71
Sharma, R., Shrivastava, S., Singh, S. K., Kumar, A., Saxena, S., & Singh, R. K. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab422 · Cited by 74
Assress, H. A., Selvarajan, R., Nyoni, H. H., Mamba, B. B., & Msagati, T. A. M. (2021) · Reviews in Environmental Science and Bio/Technology · doi:10.1007/s11157-021-09594-w · Cited by 73
Synthetic peptide branched polymers for antibacterial and biomedical applications
Shabani, S., Hadjigol, S., Li, W., Si, Z., Pranantyo, D., Chan‐Park, M. B. E., O’brien-simpson, N. M., & Qiao, G. G. (2024) · Nature Reviews Bioengineering · doi:10.1038/s44222-023-00143-4 · Cited by 71
Huang, J., Hu, P., Ye, L., Shen, Z., Chen, X., Liu, F., Xie, Y., Yu, J., Fan, X., Xiao, M., et al. (2024) · Nature Microbiology · doi:10.1038/s41564-024-01720-y · Cited by 68
Regulatory mechanisms controlling morphology and pathogenesis in Candida albicans
Kadosh, D. (2019) · Current Opinion in Microbiology · doi:10.1016/j.mib.2019.04.005 · Cited by 78
Gupta, P., Gupta, S., Sharma, M., Kumar, N., Pruthi, V., & Poluri, K. M. (2018) · ACS Omega · doi:10.1021/acsomega.8b01856 · Cited by 68
The Zebrafish as a Model Host for Invasive Fungal Infections
Rosowski, E. E., Knox, B. P., Archambault, L. S., Huttenlocher, A., Keller, N. P., Wheeler, R. T., & Davis, J. M. (2018) · Journal of Fungi · doi:10.3390/jof4040136 · Cited by 71
A novel fungal killing mechanism of propionic acid
Yun, J., & Lee, D. G. (2016) · FEMS Yeast Research · doi:10.1093/femsyr/fow089 · Cited by 70
Novel Strategies to Combat the Emerging Drug Resistance in Human Pathogenic Microbes
Qadri, H., Shah, A. H., & Mir, M. A. (2020) · Current Drug Targets · doi:10.2174/1389450121666201228123212 · Cited by 76
Wambaugh, M. A., Shakya, V. P. S., Lewis, A. J., Mulvey, M. A., & Brown, J. C. S. (2017) · PLOS Biology · doi:10.1371/journal.pbio.2001644 · Cited by 63
Potential targets for the development of new antifungal drugs
Su, H., Han, L., & Huang, X. (2018) · The Journal of Antibiotics · doi:10.1038/s41429-018-0100-9 · Cited by 69
Yang, F., Scopel, E. F. C., Li, H., Sun, L.-L., Kawar, N., Cao, Y.-B., Jiang, Y.-Y., & Berman, J. (2023) · mBio · doi:10.1128/mbio.00227-23 · Cited by 62
Systemic Antifungal Agents: Current Status and Projected Future Developments
Seyedmousavi, S., Rafati, H., İlkit, M., Tolooe, A., Hedayati, M. T., & Verweij, P. E. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-6515-1_5 · Cited by 68
Virulence and Biofilms As Promising Targets in Developing Antipathogenic Drugs Against Candidiasis
Khan, M. S., Alshehrei, F. M., Alghamdi, S., Bamaga, M. A., Althubiani, A. S., & Alam, M. Z. (2020) · Future Science OA · doi:10.2144/fsoa-2019-0027 · Cited by 69
Zhang, C.-W., Zhong, X., Zhao, Y.-S., Rajoka, M. S. R., Hashmi, M. H., Zhai, P. C., & Song, X. (2023) · Pharmacological Research - Modern Chinese Medicine · doi:10.1016/j.prmcm.2023.100262 · Cited by 61
Koselny, K., Green, J., Favazzo, L. J., Glazier, V. E., DiDone, L., Ransford, S. T., & Krysan, D. J. (2016) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.5b00134 · Cited by 60
Self-citationVincent, B. M., Langlois, J.-B., Srinivas, R., Lancaster, A. K., Scherz-Shouval, R., Whitesell, L., Tidor, B., Buchwald, S. L., & Lindquist, S. (2016) · Cell Chemical Biology · doi:10.1016/j.chembiol.2016.06.016 · Cited by 58
“Indeed, only three classes of antifungal drug are broadly used in the clinic—and none is ideal (Roemer and Krysan, 2014).”
McCallum, M. E., Rasik, C. M., Wood, J. L., & Brown, M. K. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.5b13586 · Cited by 58
In vitro and in vivo Effect of Exogenous Farnesol Exposure Against Candida auris
Nagy, F., Vitális, E., Jakab, Á., Borman, A. M., Forgács, L., Tóth, Z., Majoros, L., & Kovács, R. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.00957 · Cited by 61
Current Pharmaceutical Aspects of Synthetic Quinoline Derivatives
Tabassum, R., Ashfaq, M. H., & Oku, H. (2020) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557520999201214234735 · Cited by 55
Biernasiuk, A., Kawczyńska, M., Berecka-Rycerz, A., Rosada, B., Gumieniczek, A., Malm, A., Dzitko, K., & Łączkowski, K. Z. (2019) · Medicinal Chemistry Research · doi:10.1007/s00044-019-02433-2 · Cited by 53
Development of Antifungal Therapies Using Nanomaterials
Niemirowicz, K., Durnaś, B., Piktel, E., & Bucki, R. (2017) · Nanomedicine · doi:10.2217/nnm-2017-0052 · Cited by 55
Ahmad, A., Wani, M. Y., Patel, M., SOBRAL, A. J. F. N., Duse, A. G., Aqlan, F. M., & Al‐Bogami, A. S. (2017) · MedChemComm · doi:10.1039/c7md00440k · Cited by 51
Antifungal therapy: Novel drug delivery strategies driven by new targets
Wu, S., Song, R., Liu, T., & Li, C. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114967 · Cited by 53
Innate Inspiration: Antifungal Peptides and Other Immunotherapeutics From the Host Immune Response
Mercer, D. K., & O'Neil, D. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02177 · Cited by 50
Toward improved anti-cryptococcal drugs: Novel molecules and repurposed drugs
Krysan, D. J. (2014) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2014.12.001 · Cited by 50
Self-citationMarepu, N., Sunandamma, Y., & Pal, M. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.09.021 · Cited by 50
Tratrat, C. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200704140107 · Cited by 54
Puri, S., Kumar, R., Rojas, I. G., Salvatori, O., & Edgerton, M. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02152-18 · Cited by 48
Şahal, G., & Bilkay, I. S. (2018) · Revista da Sociedade Brasileira de Medicina Tropical · doi:10.1590/0037-8682-0136-2018 · Cited by 50
Revie, N. M., Iyer, K. R., Maxson, M. E., Zhang, J., Yan, S., Fernandes, C. M., Meyer, K. J., Chen, X., Skulska, I., Fogal, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31308-1 · Cited by 56
Serrano, R., González-Menéndez, V., Rodríguez, L., Martín, J., Tormo, J. R., & Genilloud, O. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.00649 · Cited by 56
Bolous, M., Arumugam, N., Almansour, A. I., Kumar, R. S., Maruoka, K., Antharam, V. C., & Thangamani, S. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.07.022 · Cited by 48
Clarke, S., Dumesic, P. A., Homer, C. M., O’Donoghue, A. J., Greca, F. L., Pallova, L., Majer, P., Madhani, H. D., & Craik, C. S. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1006051 · Cited by 52
Striking Back against Fungal Infections: The Utilization of Nanosystems for Antifungal Strategies
Du, W., Gao, Y., Liu, L., Sai, S., & Ding, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221810104 · Cited by 52
Metadata
- Authors
- Roemer, T., & Krysan, D. J.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- University of Rochester Medicine (US)
- ORCID
- Krysan, D. J.
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2014-05-01
- Volume
- 4
- Issue
- 5
- Pages
- a019703-a019703
- ISSN
- 2157-1422 (ISSN-L)
- PMC
- PMC3996373
- OpenAlex
- W2134122507
- Cited by
- 593
- References
- 78
- Citations by year
- 2026: 39 · 2025: 56 · 2024: 69 · 2023: 51 · 2022: 58 · 2021: 68 · 2020: 71 · 2019: 42 · 2018: 50 · 2017: 38 · 2016: 30 · 2015: 18 · 2014: 3
- Type
- posted content
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cold Spring Harbor Perspectives in Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Rochester
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases (R01AI097142, R01AI091422)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Keywords
- antifungal drug development, invasive fungal infections, antifungal drug discovery, unmet clinical needs, immunocompromised patients
- MeSH terms
- Antifungal Agents, Forecasting, Humans, Mycoses, Technology, Pharmaceutical, Treatment Outcome, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.